Banyan Biomarkers provides analytical services to pharmaceutical companies, biotechnology companies and investigators at academic research institutes.  The company has a focus on traumatic brain injury and developing assays to qualify biomarkers.  BD 

Former FDA leader von Eschenbach Named to Viamet Board of Directors

Former FDA Commissioner, Dr. Andrew von Eschenbach Finds a Home on the Board of HistoSonics
Former FDA Chief Dr. Andrew von Eschenbach Appointed to the Board of Directors For BioTime and OncoCyte

ALACHUA, Fla.--(BUSINESS WIRE)--Banyan Biomarkers, Inc. imagetoday announced that Andrew von Eschenbach, MD, former Commissioner of the Food and Drug Administration (FDA) and former Director of the National Cancer Institute (NCI), was elected to its Board of Directors.

“Banyan Biomarkers is developing a technology that would revolutionize how we diagnose and evaluate the traumatic brain injuries that are taking a devastating toll on soldiers, athletes, and accident victims. I am eager to contribute to Banyan Biomarkers’ efforts to rapidly bring such hope for a better outcome to so many in desperate need,” stated Dr. von Eschenbach.


Post a Comment

Google Analytics Alternative